The Anti-Inflammatory Effect of Taurine on Cardiovascular Disease
Abstract
:1. Introduction
2. Taurine Deficiency
3. Effects of Taurine on the Cardiovascular System
4. Beneficial Effects of Taurine in Diabetes and Obesity
5. Taurine, the Innate Immune System, and Potential Therapeutics in Cardiovascular Disease
5.1. Taurine, Toll-Like Receptors, and Cardiovascular Disease
5.2. Therapeutic Aspects of Taurine-Bromamine
5.3. Therapeutic Aspects of Taurine-Chloramine
6. Taurine as a Therapeutic in Cardiovascular Disease: Human Clinical Studies
7. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Bkaily, G.; Jazzar, A.; Normand, A.; Simon, Y.; Al-Khoury, J.; Jacques, D. Taurine and cardiac disease: State of the art and perspectives. Can. J. Physiol. Pharmacol. 2020, 98, 67–73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Obeid, O.A.; Johnston, K.; Emery, P.W. Plasma taurine and cysteine levels following an oral methionine load: Relationship with coronary heart disease. Eur. J. Clin. Nutr. 2004, 58, 105–109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maria, M.; Adeva-Andany, R.F.-C.; Yosua, L.-P.; Carlos, F.-F.; Tania, R.-M. Taurine Metabolism in Humans. J. Clin. Tri. Cas Rep. 2018, 2, 104. [Google Scholar]
- Wojcik, O.P.; Koenig, K.L.; Zeleniuch-Jacquotte, A.; Costa, M.; Chen, Y. The potential protective effects of taurine on coronary heart disease. Atherosclerosis 2010, 208, 19–25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bosevski, M.; Bosevska, G.; Stojanovska, L.; Apostolopoulos, V. CRP and fibrinogen imply clinical outcome of patients with Type-2 diabetes and coronary artery disease. Acta Biochim. Biophys. Sin. 2017, 49, 284–285. [Google Scholar] [CrossRef] [Green Version]
- Bosevski, M.; Nikolovski, P.; Stojanovska, L.; Apostolopoulos, V. Progression of carotid artery disease could stratify a risk of coronary artery disease patients with type 2 diabetes. Acta Biochim. Biophys. Sin. 2019, 51, 120–122. [Google Scholar] [CrossRef]
- Bosevski, M.; Stojanovska, L.; Apostolopoulos, V. Inflammatory biomarkers: Impact for diabetes and diabetic vascular disease. Acta Biochim. Biophys. Sin. 2015, 47, 1029–1031. [Google Scholar] [CrossRef] [Green Version]
- Hemler, E.C.; Hu, F.B. Plant-Based Diets for Cardiovascular Disease Prevention: All Plant Foods Are Not Created Equal. Curr. Atheroscler. Rep. 2019, 21, 18. [Google Scholar] [CrossRef]
- Sanchez-Sabate, R.; Sabate, J. Consumer Attitudes Towards Environmental Concerns of Meat Consumption: A Systematic Review. Int. J. Environ. Res. Public Health 2019, 16, 1220. [Google Scholar] [CrossRef] [Green Version]
- Sebastiani, G.; Herranz Barbero, A.; Borras-Novell, C.; Alsina Casanova, M.; Aldecoa-Bilbao, V.; Andreu-Fernandez, V.; Pascual Tutusaus, M.; Ferrero Martinez, S.; Gomez Roig, M.D.; Garcia-Algar, O. The Effects of Vegetarian and Vegan Diet during Pregnancy on the Health of Mothers and Offspring. Nutrients 2019, 11, 557. [Google Scholar] [CrossRef] [Green Version]
- Kawasaki, A.; Ono, A.; Mizuta, S.; Kamiya, M.; Takenaga, T.; Murakami, S. The Taurine Content of Japanese Seaweed. Adv. Exp. Med. Biol. 2017, 975 Pt 2, 1105–1112. [Google Scholar] [CrossRef]
- Kulczyński, B.; Sidor, A.; Gramza-Michałowska, A. Characteristics of Selected Antioxidative and Bioactive Compounds in Meat and Animal Origin Products. Antioxidants 2019, 8, 335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liaset, B.; Øyen, J.; Jacques, H.; Kristiansen, K.; Madsen, L. Seafood intake and the development of obesity, insulin resistance and type 2 diabetes. Nutr. Res. Rev. 2019, 32, 146–167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamori, Y.; Liu, L.; Mori, M.; Sagara, M.; Murakami, S.; Nara, Y.; Mizushima, S. Taurine as the nutritional factor for the longevity of the Japanese revealed by a world-wide epidemiological survey. Adv. Exp. Med. Biol. 2009, 643, 13–25. [Google Scholar] [CrossRef]
- Hayes, K.C.; Carey, R.E.; Schmidt, S.Y. Retinal degeneration associated with taurine deficiency in the cat. Science 1975, 188, 949–951. [Google Scholar] [CrossRef] [PubMed]
- Pion, P.D.; Kittleson, M.D.; Rogers, Q.R.; Morris, J. Myocardial failure in cats associated with low plasma taurine: A reversible cardiomyopathy. Science 1987, 237, 764–768. [Google Scholar] [CrossRef]
- Kaplan, J.L.; Stern, J.A.; Fascetti, A.J.; Larsen, J.A.; Skolnik, H.; Peddle, G.D.; Kienle, R.D.; Waxman, A.; Cocchiaro, M.; Gunther-Harrington, C.T.; et al. Taurine deficiency and dilated cardiomyopathy in golden retrievers fed commercial diets. PLoS ONE 2018, 13, e0209112. [Google Scholar] [CrossRef]
- Wharton, B.; Morley, R.; Isaacs, E.; Cole, T.; Lucas, A. Low plasma taurine and later neurodevelopment. Arch. Dis. Child. Fetal Neonatal. Ed. 2004, 89, F497–F498. [Google Scholar] [CrossRef] [Green Version]
- Ansar, M.; Ranza, E.; Shetty, M.; Paracha, S.A.; Azam, M.; Kern, I.; Iwaszkiewicz, J.; Farooq, O.; Pournaras, C.J.; Malcles, A.; et al. Taurine treatment of retinal degeneration and cardiomyopathy in a consanguineous family with SLC6A6 taurine transporter deficiency. Hum. Mol. Genet. 2019, 29, 618–623. [Google Scholar] [CrossRef] [PubMed]
- Jung, Y.-M.; Choi, M.-J. Relation of Taurine Intake during Pregnancy and Newborns’ Growth; Springer: Singapore, 2019; pp. 283–292. [Google Scholar]
- Barker, D.J.; Osmond, C.; Forsén, T.J.; Kajantie, E.; Eriksson, J.G. Trajectories of growth among children who have coronary events as adults. N. Engl. J. Med. 2005, 353, 1802–1809. [Google Scholar] [CrossRef]
- Ramila, K.C.; Jong, C.J.; Pastukh, V.; Ito, T.; Azuma, J.; Schaffer, S.W. Role of protein phosphorylation in excitation-contraction coupling in taurine deficient hearts. Am. J. Physiol. Heart Circ. Physiol. 2015, 308, H232–H239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jong, C.J.; Ito, T.; Prentice, H.; Wu, J.-Y.; Schaffer, S.W. Role of mitochondria and endoplasmic reticulum in taurine-deficiency-mediated apoptosis. Nutrients 2017, 9, 795. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mozaffarian, D.; Rimm, E.B. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 2006, 296, 1885–1899. [Google Scholar] [CrossRef] [Green Version]
- Yamori, Y.; Nara, Y.; Ikeda, K.; Mizushima, S. Is taurine a preventive nutrition. In Taurine 2; Springer: Boston, MA, USA, 1996; pp. 623–629. [Google Scholar]
- Zulli, A.; Lau, E.; Wijaya, B.P.P.; Jin, X.; Sutarga, K.; Schwartz, G.D.; Learmont, J.; Wookey, P.J.; Zinellu, A.; Carru, C.; et al. High Dietary Taurine Reduces Apoptosis and Atherosclerosis in the Left Main Coronary Artery. Hypertension 2009, 53, 1017–1022. [Google Scholar] [CrossRef] [Green Version]
- Niu, L.G.; Zhang, M.S.; Liu, Y.; Xue, W.X.; Liu, D.B.; Zhang, J.; Liang, Y.Q. Vasorelaxant effect of taurine is diminished by tetraethylammonium in rat isolated arteries. Eur. J. Pharmacol. 2008, 580, 169–174. [Google Scholar] [CrossRef] [PubMed]
- Lusis, A.J. Atherosclerosis. Nature 2000, 407, 233–241. [Google Scholar] [CrossRef]
- Schaffer, S.W.; Ju Jong, C.; Kc, R.; Azuma, J. Physiological roles of taurine in heart and muscle. J. Biomed. Sci. 2010, 17, S2. [Google Scholar] [CrossRef] [Green Version]
- Alfieri, R.R.; Cavazzoni, A.; Petronini, P.G.; Bonelli, M.A.; Caccamo, A.E.; Borghetti, A.F.; Wheeler, K.P. Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis. J. Physiol. 2002, 540, 499–508. [Google Scholar] [CrossRef]
- Takatani, T.; Takahashi, K.; Uozumi, Y.; Matsuda, T.; Ito, T.; Schaffer, S.W.; Fujio, Y.; Azuma, J. Taurine prevents the ischemia-induced apoptosis in cultured neonatal rat cardiomyocytes through Akt/caspase-9 pathway. Biochem. Biophys. Res. Commun. 2004, 316, 484–489. [Google Scholar] [CrossRef]
- Takatani, T.; Takahashi, K.; Uozumi, Y.; Shikata, E.; Yamamoto, Y.; Ito, T.; Matsuda, T.; Schaffer, S.W.; Fujio, Y.; Azuma, J. Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome. Am. J. Physiol. Cell Physiol. 2004, 287, C949–C953. [Google Scholar] [CrossRef] [Green Version]
- Hou, X.; Sun, G.; Guo, L.; Gong, Z.; Han, Y.; Bai, X. Cardioprotective effect of taurine and β-alanine against cardiac disease in myocardial ischemia and reperfusion-induced rats. Electron. J. Biotechnol. 2020, 45, 46–52. [Google Scholar] [CrossRef]
- Giugliano, D.; Maiorino, M.I.; Longo, M.; Bellastella, G.; Chiodini, P.; Esposito, K. Type 2 diabetes and risk of heart failure: A systematic review and meta-analysis from cardiovascular outcome trials. Endocrine 2019. [Google Scholar] [CrossRef] [PubMed]
- Higuchi, S.; Kohsaka, S.; Shiraishi, Y.; Katsuki, T.; Nagatomo, Y.; Mizuno, A.; Sujino, Y.; Kohno, T.; Goda, A.; Yoshikawa, T. Association of renin-angiotensin system inhibitors with long-term outcomes in patients with systolic heart failure and moderate-to-severe kidney function impairment. Eur. J. Intern. Med. 2019, 62, 58–66. [Google Scholar] [CrossRef] [PubMed]
- Soares, D.D.S.; Pinto, G.H.; Lopes, A.; Caetano, D.S.L.; Nascimento, T.G.; Andrades, M.E.; Clausell, N.; Rohde, L.E.P.; Tobar Leitao, S.A.; Biolo, A. Cardiac hypertrophy in mice submitted to a swimming protocol: Influence of training volume and intensity on myocardial renin angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2019. [Google Scholar] [CrossRef]
- Xiao, H.L.; Zhao, L.X.; Yang, J.; Tong, N.; An, L.; Liu, Q.T.; Xie, M.R.; Li, C.S. Imbalance of angiotensin-converting enzymes affects myocardial apoptosis during cardiac arrest induced by acute pulmonary embolism in a porcine model. Int. J. Mol. Med. 2019, 43, 1575–1584. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chinthammit, C.; Harrington, A.; Wild, A.; Werner, S.; Boesen, K.; Taylor, A.M.; Warholak, T.L. Retrospective Review of Exceptions for Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Recommendations for a Diabetic Medicare Population. J. Manag. Care Spec. Pharm. 2019, 25, 358–365. [Google Scholar] [CrossRef] [PubMed]
- Mohd-Tahir, N.A.; Li, S.C. Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population. PLoS ONE 2019, 14, e0212832. [Google Scholar] [CrossRef] [Green Version]
- Kangussu, L.M.; de Almeida, T.C.S.; Prestes, T.R.R.; de Andrade De Maria, M.L.; da Silva Filha, R.; Vieira, M.A.R.; Silva, A.; Ferreira, A.J. Beneficial Effects Of The Angiotensin-Converting Enzyme 2 Activator Dize In Renovascular Hypertension. Protein Pept. Lett. 2019, 26, 523–531. [Google Scholar] [CrossRef]
- Stapff, M.; Hilderbrand, S. First-line treatment of essential hypertension: A real-world analysis across four antihypertensive treatment classes. J. Clin. Hypertens. 2019, 21, 627–634. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Y.; Ma, R.; Yu, X.; Li, N.; Zhao, X.; Yu, J. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan. J. Cardiovasc. Pharmacol. Ther. 2019, 24, 450–459. [Google Scholar] [CrossRef]
- Mavromoustakos, T.; Apostolopoulos, V.; Matsoukas, J. Antihypertensive drugs that act on Renin-Angiotensin System with emphasis in AT(1) antagonists. Mini Rev. Med. Chem 2001, 1, 207–217. [Google Scholar] [CrossRef] [PubMed]
- Qaradakhi, T.; Apostolopoulos, V.; Zulli, A. Angiotensin (1–7) and Alamandine: Similarities and differences. Pharmacol. Res. 2016, 111, 820–826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qaradakhi, T.; Gadanec, L.K.; McSweeney, K.R.; Tacey, A.; Apostolopoulos, V.; Levinger, I.; Rimarova, K.; Egom, E.E.; Rodrigo, L.; Kruzliak, P.; et al. The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. Clin. Exp. Pharm. Physiol. 2020, 47, 751–758. [Google Scholar] [CrossRef] [PubMed]
- Hrenak, J.; Paulis, L.; Simko, F. Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology. Int. J. Mol. Sci. 2016, 17, 1098. [Google Scholar] [CrossRef] [PubMed]
- Skiba, D.S.; Nosalski, R.; Mikolajczyk, T.P.; Siedlinski, M.; Rios, F.J.; Montezano, A.C.; Jawien, J.; Olszanecki, R.; Korbut, R.; Czesnikiewicz-Guzik, M.; et al. Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. Br. J. Pharmacol. 2017, 174, 4055–4069. [Google Scholar] [CrossRef]
- Schaffer, S.W.; Lombardini, J.B.; Azuma, J. Interaction between the actions of taurine and angiotensin II. Amino Acids 2000, 18, 305–318. [Google Scholar] [CrossRef]
- Lv, Q.; Yang, Q.; Cui, Y.; Yang, J.; Wu, G.; Liu, M.; Ning, Z.; Cao, S.; Dong, G.; Hu, J. Effects of Taurine on ACE, ACE2 and HSP70 Expression of Hypothalamic-Pituitary-Adrenal Axis in Stress-Induced Hypertensive Rats. Adv. Exp. Med. Biol 2017, 975 Pt 2, 871–886. [Google Scholar] [CrossRef]
- Li, C.; Cao, L.; Zeng, Q.; Liu, X.; Zhang, Y.; Dai, T.; Hu, D.; Huang, K.; Wang, Y.; Wang, X.; et al. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type2 receptor expression. Cardiovasc. Drugs Ther. 2005, 19, 105–112. [Google Scholar] [CrossRef]
- Takahashi, K.; Azuma, M.; Taira, K.; Baba, A.; Yamamoto, I.; Schaffer, S.W.; Azuma, J. Effect of taurine on angiotensin II-induced hypertrophy of neonatal rat cardiac cells. J. Cardiovasc. Pharmacol. 1997, 30, 725–730. [Google Scholar] [CrossRef] [PubMed]
- Azuma, M.; Takahashi, K.; Fukuda, T.; Ohyabu, Y.; Yamamoto, I.; Kim, S.; Iwao, H.; Schaffer, S.W.; Azuma, J. Taurine attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac myocytes. Eur. J. Pharmacol. 2000, 403, 181–188. [Google Scholar] [CrossRef]
- Takahahsi, K.; Azuma, M.; Baba, A.; Schaffer, S.; Azuma, J. Taurine improves angiotensin II-induced hypertrophy of cultured neonatal rat heart cells. Adv. Exp. Med. Biol 1998, 442, 129–135. [Google Scholar] [PubMed]
- Gavrovskaya, L.K.; Ryzhova, O.V.; Safonova, A.F.; Matveev, A.K.; Sapronov, N.S. Protective effect of taurine on rats with experimental insulin-dependent diabetes mellitus. Bull. Exp. Biol. Med. 2008, 146, 226–228. [Google Scholar] [CrossRef] [PubMed]
- Tenner, T.E.; Zhang, X.J.; Lombardini, J.B. Hypoglycemic Effects of Taurine in the Alloxan-Treated Rabbit, a Model for Type 1 Diabetes. In Taurine 5; Springer: Boston, MA, USA, 2003; Volume 526, pp. 97–104. [Google Scholar] [CrossRef]
- Winiarska, K.; Szymanski, K.; Gorniak, P.; Dudziak, M.; Bryla, J. Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie 2009, 91, 261–270. [Google Scholar] [CrossRef] [PubMed]
- L’Amoreaux, W.J.; Cuttitta, C.; Santora, A.; Blaize, J.F.; Tachjadi, J.; El Idrissi, A. Taurine regulates insulin release from pancreatic beta cell lines. J. Biomed. Sci 2010, 17 (Suppl. 1), S11. [Google Scholar] [CrossRef] [Green Version]
- Kim, K.S.; Oh, D.H.; Kim, J.Y.; Lee, B.G.; You, J.S.; Chang, K.J.; Chung, H.J.; Yoo, M.C.; Yang, H.I.; Kang, J.H.; et al. Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes. Exp. Mol. Med. 2012, 44, 665–673. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brons, C.; Spohr, C.; Storgaard, H.; Dyerberg, J.; Vaag, A. Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Eur. J. Clin. Nutr. 2004, 58, 1239–1247. [Google Scholar] [CrossRef]
- Ades, P.A.; Savage, P.D. Obesity in coronary heart disease: An unaddressed behavioral risk factor. Prev. Med. 2017, 104, 117–119. [Google Scholar] [CrossRef]
- Jin, J. Obesity and the Heart. JAMA 2013, 310, 2113. [Google Scholar] [CrossRef] [Green Version]
- Rider, O.J.; Lewis, A.J.; Neubauer, S. Structural and metabolic effects of obesity on the myocardium and the aorta. Obes. Facts 2014, 7, 329–338. [Google Scholar] [CrossRef]
- Csige, I.; Ujvárosy, D.; Szabó, Z.; Lőrincz, I.; Paragh, G.; Harangi, M.; Somodi, S. The impact of obesity on the cardiovascular system. J. Diabetes Res. 2018. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Nakayama, T. Inflammation, a link between obesity and cardiovascular disease. Mediat. Inflamm. 2010. [Google Scholar] [CrossRef] [Green Version]
- Rosa, F.T.; Freitas, E.C.; Deminice, R.; Jordao, A.A.; Marchini, J.S. Oxidative stress and inflammation in obesity after taurine supplementation: A double-blind, placebo-controlled study. Eur. J. Nutr. 2014, 53, 823–830. [Google Scholar] [CrossRef] [PubMed]
- Murakami, S. Role of taurine in the pathogenesis of obesity. Mol. Nutr. Food Res. 2015, 59, 1353–1363. [Google Scholar] [CrossRef] [PubMed]
- Tsuboyama-Kasaoka, N.; Shozawa, C.; Sano, K.; Kamei, Y.; Kasaoka, S.; Hosokawa, Y.; Ezaki, O. Taurine (2-aminoethanesulfonic acid) deficiency creates a vicious circle promoting obesity. Endocrinology 2006, 147, 3276–3284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, K.S.; Jang, M.J.; Fang, S.; Yoon, S.G.; Kim, I.Y.; Seong, J.K.; Yang, H.-I.; Hahm, D.H. Anti-obesity effect of taurine through inhibition of adipogenesis in white fat tissue but not in brown fat tissue in a high-fat diet-induced obese mouse model. Amino Acids 2019, 51, 245–254. [Google Scholar] [CrossRef]
- Martens, F.M.; Rabelink, T.J.; op’t Roodt, J.; de Koning, E.J.; Visseren, F.L. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur. Heart J. 2006, 27, 1605–1609. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.; Lee, S.; Zhang, H.; Hill, M.A.; Zhang, C.; Park, Y. Interaction of IL-6 and TNF-α contributes to endothelial dysfunction in type 2 diabetic mouse hearts. PLoS ONE 2017, 12, e0187189. [Google Scholar] [CrossRef] [Green Version]
- Tardif, J.C.; Kouz, S.; Waters, D.D.; Bertrand, O.F.; Diaz, R.; Maggioni, A.P.; Pinto, F.J.; Ibrahim, R.; Gamra, H.; Kiwan, G.S.; et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N. Engl. J. Med. 2019, 381, 2497–2505. [Google Scholar] [CrossRef]
- Kimbrell, D.A.; Beutler, B. The evolution and genetics of innate immunity. Nat. Rev. Genet. 2001, 2, 256–267. [Google Scholar] [CrossRef]
- Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 2010, 11, 373. [Google Scholar] [CrossRef]
- Zarember, K.A.; Godowski, P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168, 554–561. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aderem, A.; Ulevitch, R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406, 782–787. [Google Scholar] [CrossRef] [PubMed]
- Kurup, S.P.; Tarleton, R.L. Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat. Commun. 2013, 4, 2616. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Komai, K.; Shichita, T.; Ito, M.; Kanamori, M.; Chikuma, S.; Yoshimura, A. Role of scavenger receptors as damage-associated molecular pattern receptors in Toll-like receptor activation. Int. Immunol. 2017, 29, 59–70. [Google Scholar] [CrossRef] [PubMed]
- Bagchi, A.; Herrup, E.A.; Warren, H.S.; Trigilio, J.; Shin, H.-S.; Valentine, C.; Hellman, J. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 2007, 178, 1164–1171. [Google Scholar] [CrossRef]
- Yamamoto, M.; Sato, S.; Hemmi, H.; Hoshino, K.; Kaisho, T.; Sanjo, H.; Takeuchi, O.; Sugiyama, M.; Okabe, M.; Takeda, K. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301, 640–643. [Google Scholar] [CrossRef]
- Mäkelä, S.M.; Strengell, M.; Pietilä, T.E.; Österlund, P.; Julkunen, I. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J. Leukoc. Biol. 2009, 85, 664–672. [Google Scholar] [CrossRef]
- Butcher, S.K.; O’Carroll, C.E.; Wells, C.A.; Carmody, R.J. Toll-like receptors drive specific patterns of tolerance and training on restimulation of macrophages. Front. Immunol. 2018, 9, 933. [Google Scholar] [CrossRef] [Green Version]
- Palazzo, M.; Gariboldi, S.; Zanobbio, L.; Dusio, G.F.; Selleri, S.; Bedoni, M.; Balsari, A.; Rumio, C. Cross-talk among Toll-like receptors and their ligands. Int. Immunol. 2008, 20, 709–718. [Google Scholar] [CrossRef] [Green Version]
- Rosenberger, K.; Derkow, K.; Dembny, P.; Krüger, C.; Schott, E.; Lehnardt, S. The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration. J. Neuroinflamm. 2014, 11, 1–20. [Google Scholar] [CrossRef] [Green Version]
- Frantz, S.; Ertl, G.; Bauersachs, J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2007, 4, 444–454. [Google Scholar] [CrossRef] [PubMed]
- Dong, B.; Qi, D.; Yang, L.; Huang, Y.; Xiao, X.; Tai, N.; Wen, L.; Wong, F.S. TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2012, 303, H732–H742. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lu, Z.; Zhang, X.; Li, Y.; Jin, J.; Huang, Y. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J. Endocrinol. 2013, 216, 61–71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roshan, M.H.; Tambo, A.; Pace, N.P. The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis. Int. J. Inflamm. 2016. [Google Scholar] [CrossRef] [Green Version]
- Lu, Z.; Zhang, X.; Li, Y.; Lopes-Virella, M.F.; Huang, Y. TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes. Immunobiology 2015, 220, 1246–1254. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dasu, M.R.; Devaraj, S.; Park, S.; Jialal, I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010, 33, 861–868. [Google Scholar] [CrossRef] [Green Version]
- Ehses, J.; Meier, D.; Wueest, S.; Rytka, J.; Boller, S.; Wielinga, P.; Schraenen, A.; Lemaire, K.; Debray, S.; Van Lommel, L. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010, 53, 1795–1806. [Google Scholar] [CrossRef]
- Hardenberg, G.; Yao, Y.; Piccirillo, C.A.; Levings, M.K.; Steiner, T.S. Toll-like receptor 5 deficiency protects from wasting disease in a T cell transfer colitis model in T cell receptor-β-deficient mice. Inflamm. Bowel Dis. 2012, 18, 85–93. [Google Scholar] [CrossRef]
- Ding, Y.; Subramanian, S.; Montes, V.N.; Goodspeed, L.; Wang, S.; Han, C.; Teresa, A.S., III; Kim, J.; O’Brien, K.D.; Chait, A. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor–deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1596–1604. [Google Scholar] [CrossRef] [Green Version]
- Pierre, N.; Deldicque, L.; Barbé, C.; Naslain, D.; Cani, P.D.; Francaux, M. Toll-like receptor 4 knockout mice are protected against endoplasmic reticulum stress induced by a high-fat diet. PLoS ONE 2013, 8, e65061. [Google Scholar] [CrossRef]
- Liu, C.-L.; Santos, M.M.; Fernandes, C.; Liao, M.; Iamarene, K.; Zhang, J.-Y.; Sukhova, G.K.; Shi, G.-P. Toll-like receptor 7 deficiency protects apolipoprotein E-deficient mice from diet-induced atherosclerosis. Sci. Rep. 2017, 7, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Ishibashi, M.; Sayers, S.; D’Armiento, J.M.; Tall, A.R.; Welch, C.L. TLR3 deficiency protects against collagen degradation and medial destruction in murine atherosclerotic plaques. Atherosclerosis 2013, 229, 52–61. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Zhang, Y. Toll-like receptor-6 (TLR6) deficient mice are protected from myocardial fibrosis induced by high fructose feeding through anti-oxidant and inflammatory signaling pathway. Biochem. Biophys. Res. Commun. 2016, 473, 388–395. [Google Scholar] [CrossRef]
- Misch, E.A.; Macdonald, M.; Ranjit, C.; Sapkota, B.R.; Wells, R.D.; Siddiqui, M.R.; Kaplan, G.; Hawn, T.R. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl. Trop. Dis. 2008, 2, e231. [Google Scholar] [CrossRef] [Green Version]
- De Kleijn, D.P.; Chong, S.Y.; Wang, X.; Yatim, S.M.J.; Fairhurst, A.-M.; Vernooij, F.; Zharkova, O.; Chan, M.Y.; Foo, R.S.; Timmers, L. Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 2019, 115, 1791–1803. [Google Scholar] [CrossRef] [PubMed]
- Xiao, W.; Liu, Z.; Lin, J.; Li, J.; Wu, K.; Ma, Y.; Gong, Y.; Liu, Z. Polymorphisms in TLR1, TLR6 and TLR10 genes and the risk of Graves’ disease. Autoimmunity 2015, 48, 13–18. [Google Scholar] [CrossRef] [PubMed]
- Johnson, C.M.; Lyle, E.A.; Omueti, K.O.; Stepensky, V.A.; Yegin, O.; Alpsoy, E.; Hamann, L.; Schumann, R.R.; Tapping, R.I. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J. Immunol. 2007, 178, 7520–7524. [Google Scholar] [CrossRef] [PubMed]
- Schröder, N.W.; Diterich, I.; Zinke, A.; Eckert, J.; Draing, C.; Baehr, V.V.; Hassler, D.; Priem, S.; Hahn, K.; Michelsen, K.S. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J. Immunol. 2005, 175, 2534–2540. [Google Scholar] [CrossRef] [Green Version]
- Greene, J.A.; Sam-Agudu, N.; John, C.C.; Opoka, R.O.; Zimmerman, P.A.; Kazura, J.W. Toll-like receptor polymorphisms and cerebral malaria: TLR2 Δ22 polymorphism is associated with protection from cerebral malaria in a case control study. Malar. J. 2012, 11, 47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zimmer, B.; Ewaleifoh, O.; Harschnitz, O.; Lee, Y.-S.; Peneau, C.; McAlpine, J.L.; Liu, B.; Tchieu, J.; Steinbeck, J.A.; Lafaille, F. Human iPSC-derived trigeminal neurons lack constitutive TLR3-dependent immunity that protects cortical neurons from HSV-1 infection. Proc. Natl. Acad. Sci. USA 2018, 115, E8775–E8782. [Google Scholar] [CrossRef] [Green Version]
- Huik, K.; Avi, R.; Pauskar, M.; Kallas, E.; Jõgeda, E.-L.; Karki, T.; Marsh, K.; Des Jarlais, D.; Uusküla, A.; Lutsar, I. Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infect. Genet. Evol. 2013, 20, 78–82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ducloux, D.; Deschamps, M.; Yannaraki, M.; Ferrand, C.; Bamoulid, J.; Saas, P.; Kazory, A.; Chalopin, J.-M.; Tiberghien, P. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int. 2005, 67, 2454–2461. [Google Scholar] [CrossRef] [Green Version]
- Al-Daghri, N.M.; Clerici, M.; Al-Attas, O.; Forni, D.; Alokail, M.S.; Alkharfy, K.M.; Sabico, S.; Mohammed, A.K.; Cagliani, R.; Sironi, M. A nonsense polymorphism (R392X) in TLR5 protects from obesity but predisposes to diabetes. J. Immunol. 2013, 190, 3716–3720. [Google Scholar] [CrossRef]
- Hamann, L.; Koch, A.; Sur, S.; Hoefer, N.; Glaeser, C.; Schulz, S.; Gross, M.; Franke, A.; Nöthlings, U.; Zacharowski, K. Association of a common TLR-6 polymorphism with coronary artery disease–implications for healthy ageing? Immun. Ageing 2013, 10, 43. [Google Scholar] [CrossRef] [Green Version]
- Schott, E.; Witt, H.; Neumann, K.; Taube, S.; Oh, D.-Y.; Schreier, E.; Vierich, S.; Puhl, G.; Bergk, A.; Halangk, J. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J. Hepatol. 2007, 47, 203–211. [Google Scholar] [CrossRef]
- Chen, Z.; Ma, G.; Qian, Q.; Yao, Y.; Feng, Y.; Tang, C. Toll-like receptor 8 polymorphism and coronary artery disease. Mol. Biol. Rep. 2009, 36, 1897–1901. [Google Scholar] [CrossRef]
- Hold, G.L.; Rabkin, C.S.; Gammon, M.D.; Berry, S.H.; Smith, M.G.; Lissowska, J.; Risch, H.A.; Chow, W.-H.; Mowat, N.A.G.; Vaughan, T.L. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ. 2009, 18, 117. [Google Scholar] [CrossRef] [PubMed]
- Xiang, Q.; Zhu, L.; Zheng, K.; Ding, Y.; Chen, N.; Liu, G.; He, Q. Association of toll-like receptor 10 polymorphisms with pediatric pneumococcal meningitis. Apmis 2020, 128, 335–342. [Google Scholar] [CrossRef]
- Gao, W.; Xiong, Y.; Li, Q.; Yang, H. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: A journey from molecular to nano therapeutics. Front. Physiol. 2017, 8, 508. [Google Scholar] [CrossRef]
- Grabowski, M.; Murgueitio, M.S.; Bermudez, M.; Wolber, G.; Weindl, G. The novel small-molecule antagonist MMG-11 preferentially inhibits TLR2/1 signaling. Biochem. Pharmacol. 2020, 171, 113687. [Google Scholar] [CrossRef]
- Cen, X.; Zhu, G.; Yang, J.; Yang, J.; Guo, J.; Jin, J.; Nandakumar, K.S.; Yang, W.; Yin, H.; Liu, S. TLR1/2 Specific Small-Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes. Adv. Sci. 2019, 6, 1802042. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Z.; Tian, B.; Chen, H.; Wang, P.; Brasier, A.R.; Zhou, J. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur. J. Med. Chem. 2018, 151, 450–461. [Google Scholar] [CrossRef] [PubMed]
- Bhattacharyya, S.; Wang, W.; Tamaki, Z.; Shi, B.; Yeldandi, A.; Tsukimi, Y.; Yamasaki, M.; Varga, J. Pharmacological inhibition of toll-like receptor-4 signaling by TAK242 prevents and induces regression of experimental organ fibrosis. Front. Immunol. 2018, 9, 2434. [Google Scholar] [CrossRef] [Green Version]
- Fazzino, F.; Urbina, M.; Mata, S.; Lima, L. Taurine transport and transporter localization in peripheral blood lymphocytes of controls and major depression patients. In Taurine 6; Springer: Boston, MA, USA, 2006; pp. 423–426. [Google Scholar]
- Marcinkiewicz, J.; Kontny, E. Taurine and inflammatory diseases. Amino Acids 2014, 46, 7–20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, C.; Cha, Y.-N. Production of reactive oxygen and nitrogen species in phagocytes is regulated by taurine chloramine. In Taurine 7; Springer: Boston, MA, USA, 2009; pp. 463–472. [Google Scholar]
- Wang, L.; Zhao, N.; Zhang, F.; Yue, W.; Liang, M. Effect of taurine on leucocyte function. Eur. J. Pharmacol. 2009, 616, 275–280. [Google Scholar] [CrossRef]
- Jong, C.J.; Azuma, J.; Schaffer, S. Mechanism underlying the antioxidant activity of taurine: Prevention of mitochondrial oxidant production. Amino Acids 2012, 42, 2223–2232. [Google Scholar] [CrossRef]
- Lima, L.; Obregón, F.; Urbina, M.; Carreira, I.; Baccichet, E.; Peña, S. Taurine Concentration in Human Blood Peripheral Lymphocytes. In Taurine 5; Springer: Boston, MA, USA, 2003; pp. 297–304. [Google Scholar]
- Kearns, S.; Dawson, R. Cytoprotective effect of taurine against hypochlorous acid toxicity to PC12 cells. In Taurine 4; Springer: Boston, MA, USA, 2002; pp. 563–570. [Google Scholar]
- Heidari, R.; Babaei, H.; Eghbal, M.A. Cytoprotective effects of taurine against toxicity induced by isoniazid and hydrazine in isolated rat hepatocytes. Arh. Hig. Rada Toksikol. 2013, 64, 201–209. [Google Scholar] [CrossRef] [Green Version]
- Kim, T.; Kim, A.K. Taurine enhances anticancer activity of cisplatin in human cervical cancer cells. In Taurine 8; Springer: Boston, MA, USA, 2013; pp. 189–198. [Google Scholar]
- Miao, J.; Zheng, L.; Zhang, J.; Ma, Z.; Zhu, W.; Zou, S. The effect of taurine on the toll-like receptors/nuclear factor kappa B (TLRs/NF-κB) signaling pathway in Streptococcus uberis-induced mastitis in rats. Int. Immunopharmacol. 2011, 11, 1740–1746. [Google Scholar] [CrossRef]
- Abdih, H.; Kelly, C.; Bouchier-Hayes, D.; Barry, M.; Kearns, S. Taurine prevents interleukin-2-induced acute lung injury in rats. Eur. Surg. Res. 2000, 32, 347–352. [Google Scholar] [CrossRef]
- Schuller-Levis, G.; Gordon, R.E.; Wang, C.; Park, S.Y.; Park, E. Protection of bleomycin-induced fibrosis and inflammation by taurine. Int. Immunopharmacol. 2009, 9, 971–977. [Google Scholar] [CrossRef]
- Gurujeyalakshmi, G.; Wang, Y.; Giri, S.N. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide 2000, 4, 399–411. [Google Scholar] [CrossRef] [PubMed]
- Schuller-Levis, G.B.; Gordon, R.E.; Wang, C.; Park, E. Taurine reduces lung inflammation and fibrosis caused by bleomycin. In Taurine 5; Springer: Boston, MA, USA, 2003; pp. 395–402. [Google Scholar]
- Giri, S.N. The combined treatment with taurine and niacin blocks the bleomycin-induced activation of nuclear factor-kB and lung fibrosis. In Taurine 5; Springer: Boston, MA, USA, 2003; pp. 381–394. [Google Scholar]
- Bhavsar, T.M.; Patel, S.N.; Lau-Cam, C.A. Protective action of taurine, given as a pretreatment or as a posttreatment, against endotoxin-induced acute lung inflammation in hamsters. J. Biomed. Sci. 2010, 17, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bhavsar, T.M.; Cantor, J.O.; Patel, S.N.; Lau-Cam, C.A. Attenuating effect of taurine on lipopolysaccharide-induced acute lung injury in hamsters. Pharmacol. Res. 2009, 60, 418–428. [Google Scholar] [CrossRef]
- De Oliveira Ramos, C.; Campos, K.K.D.; de Paula Costa, G.; Cangussú, S.D.; Talvani, A.; Bezerra, F.S. Taurine treatment decreases inflammation and oxidative stress in lungs of adult mice exposed to cigarette smoke. Regul. Toxicol. Pharmacol. 2018, 98, 50–57. [Google Scholar] [CrossRef]
- Nakajima, Y.; Osuka, K.; Seki, Y.; Gupta, R.C.; Hara, M.; Takayasu, M.; Wakabayashi, T. Taurine reduces inflammatory responses after spinal cord injury. J. Neurotrauma 2010, 27, 403–410. [Google Scholar] [CrossRef] [PubMed]
- Sobrido-Cameán, D.; Fernández-López, B.; Pereiro, N.; Lafuente, A.; Rodicio, M.C.; Barreiro-Iglesias, A. Taurine promotes axonal regeneration after a complete spinal cord injury in lampreys. J. Neurotrauma 2020, 37, 899–903. [Google Scholar] [CrossRef]
- Niu, X.; Zheng, S.; Liu, H.; Li, S. Protective effects of taurine against inflammation, apoptosis, and oxidative stress in brain injury. Mol. Med. Rep. 2018, 18, 4516–4522. [Google Scholar] [CrossRef] [Green Version]
- Su, Y.; Fan, W.; Ma, Z.; Wen, X.; Wang, W.; Wu, Q.; Huang, H. Taurine improves functional and histological outcomes and reduces inflammation in traumatic brain injury. Neuroscience 2014, 266, 56–65. [Google Scholar] [CrossRef]
- Chowdhury, S.; Sinha, K.; Banerjee, S.; Sil, P.C. Taurine protects cisplatin induced cardiotoxicity by modulating inflammatory and endoplasmic reticulum stress responses. Biofactors 2016, 42, 647–664. [Google Scholar] [CrossRef]
- Saad, S.Y.; Al-Rikabi, A.C. Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy 2002, 48, 42–48. [Google Scholar] [CrossRef]
- Sato, S.; Yamate, J.; Saito, T.; Hosokawa, T.; Saito, S.; Kurasaki, M. Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedebergs Arch. Pharmacol. 2002, 365, 277–283. [Google Scholar] [CrossRef]
- Tsunekawa, M.; Wang, S.; Kato, T.; Yamashita, T.; Ma, N. Taurine administration mitigates cisplatin induced acute nephrotoxicity by decreasing DNA damage and inflammation: An immunocytochemical study. In Taurine 10; Springer: Boston, MA, USA, 2017; pp. 703–716. [Google Scholar]
- Azab, S.S.; Ismail, N.N.; Hosni, H.E.D.; Abd El Fatah, M. The defensive role of taurine against gonadotoxicity and testicular apoptosis effects induced by cisplatin in rats. J. Infect. Chemother. 2020, 26, 51–57. [Google Scholar] [CrossRef] [PubMed]
- Rajapandi, T.; Ackie, K.; Hegde, K.R. Anti-plasmodial Activity of a Non-protein Amino Acid Taurine. Sciences 2019, 5, 34–37. [Google Scholar] [CrossRef] [Green Version]
- Delić, D.; Warskulat, U.; Borsch, E.; Al-Qahtani, S.; Al-Quraishi, S.; Häussinger, D.; Wunderlich, F. Loss of ability to self-heal malaria upon taurine transporter deletion. Infect. Immun. 2010, 78, 1642–1649. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schuller-Levis, G.; Mehta, P.D.; Rudelli, R.; Sturman, J. Immunologic consequences of taurine deficiency in cats. J. Leukoc. Biol. 1990, 47, 321–331. [Google Scholar] [CrossRef]
- Mochizuki, T.; Satsu, H.; Shimizu, M. Signaling pathways involved in tumor necrosis factor α-induced upregulation of the taurine transporter in Caco-2 cells. Febs Lett. 2005, 579, 3069–3074. [Google Scholar] [CrossRef] [Green Version]
- Marcinkiewicz, J. Taurine bromamine (TauBr)--its role in immunity and new perspectives for clinical use. J. Biomed. Sci. 2010, 17 (Suppl. 1), S3. [Google Scholar] [CrossRef] [Green Version]
- Che, Y.; Hou, L.; Sun, F.; Zhang, C.; Liu, X.; Piao, F.; Zhang, D.; Li, H.; Wang, Q. Taurine protects dopaminergic neurons in a mouse Parkinson’s disease model through inhibition of microglial M1 polarization. Cell Death Dis. 2018, 9, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Henderson, J.P.; Byun, J.; Williams, M.V.; Mueller, D.M.; McCormick, M.L.; Heinecke, J.W. Production of brominating intermediates by myeloperoxidase. A transhalogenation pathway for generating mutagenic nucleobases during inflammation. J. Biol. Chem. 2001, 276, 7867–7875. [Google Scholar] [CrossRef] [Green Version]
- Aldridge, R.E.; Chan, T.; van Dalen, C.J.; Senthilmohan, R.; Winn, M.; Venge, P.; Town, G.I.; Kettle, A.J. Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics. Free Radic. Biol. Med. 2002, 33, 847–856. [Google Scholar] [CrossRef]
- Marcinkiewicz, J.; Chain, B.; Nowak, B.; Grabowska, A.; Bryniarski, K.; Baran, J. Antimicrobial and cytotoxic activity of hypochlorous acid: Interactions with taurine and nitrite. Inflamm. Res. 2000, 49, 280–289. [Google Scholar] [CrossRef] [PubMed]
- Marcinkiewicz, J.; Biedroń, R.; Białecka, A.; Kasprowicz, A.; Mak, M.; Targosz, M. Susceptibility of Propionibacterium acnes and Staphylococcus epidermidis to killing by MPO-halide system products. Implication for taurine bromamine as a new candidate for topical therapy in treating acne vulgaris. Arch. Immunol. Ther. Exp. 2006, 54, 61–68. [Google Scholar] [CrossRef] [PubMed]
- Wagner, B.A.; Reszka, K.J.; McCormick, M.L.; Britigan, B.E.; Evig, C.B.; Patrick Burns, C. Role of thiocyanate, bromide and hypobromous acid in hydrogen peroxide-induced apoptosis. Free Radic. Res. 2004, 38, 167–175. [Google Scholar] [CrossRef]
- Marcinkiewicz, J.; Mak, M.; Bobek, M.; Biedroń, R.; Białecka, A.; Koprowski, M.; Kontny, E.; Maśliński, W. Is there a role of taurine bromamine in inflammation? Interactive effects with nitrite and hydrogen peroxide. Inflamm. Res. 2005, 54, 42–49. [Google Scholar] [CrossRef] [PubMed]
- Marcinkiewicz, J.; Wojas-Pelc, A.; Walczewska, M.; Lipko-Godlewska, S.; Jachowicz, R.; Maciejewska, A.; Bialecka, A.; Kasprowicz, A. Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris: A pilot study. Eur. J. Dermatol. EJD 2008, 18, 433–439. [Google Scholar] [CrossRef] [PubMed]
- Tokunaga, S.; Kanayama, A.; Miyamoto, Y. Modification of IkappaBalpha by taurine bromamine inhibits tumor necrosis factor alpha-induced NF-kappaB activation. Inflamm. Res. Off. J. Eur. Histamine Res. Soc. 2007, 56, 479–486. [Google Scholar] [CrossRef]
- Kontny, E.; Chorąży-Massalska, M.; Rudnicka, W.; Marcinkiewicz, J.; Maśliński, W. Comparison of taurine chloramine and taurine bromamine effects on rheumatoid arthritis synoviocytes. Amino Acids 2007, 32, 447–452. [Google Scholar] [CrossRef]
- Olszanecki, R.; Marcinkiewicz, J. Taurine chloramine and taurine bromamine induce heme oxygenase-1 in resting and LPS-stimulated J774. 2 macrophages. Amino Acids 2004, 27, 29–35. [Google Scholar] [CrossRef]
- Araujo, J.A.; Zhang, M.; Yin, F. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front. Pharmacol. 2012, 3, 119. [Google Scholar] [CrossRef] [Green Version]
- Iwasaki, H.; Takeuchi, O.; Teraguchi, S.; Matsushita, K.; Uehata, T.; Kuniyoshi, K.; Satoh, T.; Saitoh, T.; Matsushita, M.; Standley, D.M. The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR–IL-1R by controlling degradation of regnase-1. Nat. Immunol. 2011, 12, 1167–1175. [Google Scholar] [CrossRef]
- Sugiyama, S.; Kugiyama, K.; Aikawa, M.; Nakamura, S.; Ogawa, H.; Libby, P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: Involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1309–1314. [Google Scholar] [CrossRef]
- Bergt, C.; Pennathur, S.; Fu, X.; Byun, J.; O’Brien, K.; McDonald, T.O.; Singh, P.; Anantharamaiah, G.; Chait, A.; Brunzell, J. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA 2004, 101, 13032–13037. [Google Scholar] [CrossRef] [Green Version]
- Panasenko, O.; Gorudko, I.; Sokolov, A. Hypochlorous acid as a precursor of free radicals in living systems. Biochemistry 2013, 78, 1466–1489. [Google Scholar] [CrossRef] [PubMed]
- Nagl, M.; Hess, M.W.; Pfaller, K.; Hengster, P.; Gottardi, W. Bactericidal Activity of MicromolarN-Chlorotaurine: Evidence for Its Antimicrobial Function in the Human Defense System. Antimicrob. Agents Chemother. 2000, 44, 2507–2513. [Google Scholar] [CrossRef] [Green Version]
- Gottardi, W.; Hagleitner, M.; Nagl, M. N, N-Dichlorotaurine: Chemical and Bactericidal Properties. Arch. Pharm. Int. J. Pharm. Med. Chem. 2005, 338, 473–483. [Google Scholar] [CrossRef] [PubMed]
- Nagl, M.; Lass-Flörl, C.; Neher, A.; Gunkel, A.; Gottardi, W. Enhanced fungicidal activity of N-chlorotaurine in nasal secretion. J. Antimicrob. Chemother. 2001, 47, 871–874. [Google Scholar] [CrossRef]
- Woods, A.A.; Linton, S.M.; Davies, M.J. Detection of HOCl-mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem. J. 2003, 370, 729–735. [Google Scholar] [CrossRef]
- Whiteman, M.; Chu, S.H.; Siau, J.L.; Rose, P.; Sabapathy, K.; Schantz, J.-T.; Cheung, N.S.; Spencer, J.P.; Armstrong, J.S. The pro-inflammatory oxidant hypochlorous acid induces Bax-dependent mitochondrial permeabilisation and cell death through AIF-/EndoG-dependent pathways. Cell. Signal. 2007, 19, 705–714. [Google Scholar] [CrossRef]
- Yang, Y.-t.T.; Whiteman, M.; Gieseg, S.P. HOCl causes necrotic cell death in human monocyte derived macrophages through calcium dependent calpain activation. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 2012, 1823, 420–429. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.-Z.; Wang, L.; Zhang, J.-J.; Xiong, X.-M.; Zhang, D.; Tang, X.-M.; Luo, X.-J.; Ma, Q.-L.; Peng, J. Vascular peroxide 1 promotes ox-LDL-induced programmed necrosis in endothelial cells through a mechanism involving β-catenin signaling. Atherosclerosis 2018, 274, 128–138. [Google Scholar] [CrossRef]
- Laggner, H.; Muellner, M.K.; Schreier, S.; Sturm, B.; Hermann, M.; Exner, M.; Laggner, H.; Muellner, M.K.; Schreier, S.; Sturm, B. Hydrogen sulphide: A novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radic. Res. 2007, 41, 741–747. [Google Scholar] [CrossRef]
- Shepherd, J.; Hilderbrand, S.A.; Waterman, P.; Heinecke, J.W.; Weissleder, R.; Libby, P. A fluorescent probe for the detection of myeloperoxidase activity in atherosclerosis-associated macrophages. Chem. Biol. 2007, 14, 1221–1231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ismael, F.O.; Proudfoot, J.M.; Brown, B.E.; van Reyk, D.M.; Croft, K.D.; Davies, M.J.; Hawkins, C.L. Comparative reactivity of the myeloperoxidase-derived oxidants HOCl and HOSCN with low-density lipoprotein (LDL): Implications for foam cell formation in atherosclerosis. Arch. Biochem. Biophys. 2015, 573, 40–51. [Google Scholar] [CrossRef]
- Sugiyama, S.; Okada, Y.; Sukhova, G.K.; Virmani, R.; Heinecke, J.W.; Libby, P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 2001, 158, 879–891. [Google Scholar] [CrossRef] [Green Version]
- Hasanpour, Z.; Javanmard, S.H.; Gharaaty, M.; Sadeghi, M. Association between serum myeloperoxidase levels and coronary artery disease in patients without diabetes, hypertension, obesity, and hyperlipidemia. Adv. Biomed. Res. 2016, 5. [Google Scholar] [CrossRef]
- Ghoshal, K.; Das, S.; Aich, K.; Goswami, S.; Chowdhury, S.; Bhattacharyya, M. A novel sensor to estimate the prevalence of hypochlorous (HOCl) toxicity in individuals with type 2 diabetes and dyslipidemia. Clin. Chim. Acta 2016, 458, 144–153. [Google Scholar] [CrossRef]
- Kim, K.S.; Park, E.K.; Ju, S.M.; Jung, H.-S.; Bang, J.S.; Kim, C.; Lee, Y.-A.; Hong, S.-J.; Lee, S.-H.; Yang, H.-I. Taurine chloramine differentially inhibits matrix metalloproteinase 1 and 13 synthesis in interleukin-1β stimulated fibroblast-like synoviocytes. Arthritis Res. Ther. 2007, 9, R80. [Google Scholar] [CrossRef] [Green Version]
- Kim, C.; Cha, Y.-N. Taurine chloramine produced from taurine under inflammation provides anti-inflammatory and cytoprotective effects. Amino Acids 2014, 46, 89–100. [Google Scholar] [CrossRef]
- Marcinkiewicz, J.; Kurnyta, M.; Biedroń, R.; Bobek, M.; Kontny, E.; Maśliński, W. Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms. In Taurine 6; Springer: Boston, MA, USA, 2006; pp. 481–492. [Google Scholar]
- Iwasaki, A.; Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327, 291–295. [Google Scholar] [CrossRef] [Green Version]
- Marcinkiewicz, J.; Grabowska, A.; Bereta, J.; Stelmaszynska, T. Taurine chloramine, a product of activated neutrophils, inhibits in vitro the generation of nitric oxide and other macrophage inflammatory mediators. J. Leukoc. Biol. 1995, 58, 667–674. [Google Scholar] [CrossRef]
- Chorazy-Massalska, M.; Kontny, E.; Kornatka, A.; Rell-Bakalarska, M.; Marcinkiewicz, J.; Maslinski, W. The effect of taurine chloramine on pro-inflammatory cytokine production by peripheral blood mononuclear cells isolated from rheumatoid arthritis and osteoarthritis patients. Clin. Exp. Rheumatol. 2004, 22, 692–698. [Google Scholar]
- Barua, M.; Liu, Y.; Quinn, M.R. Taurine chloramine inhibits inducible nitric oxide synthase and TNF-alpha gene expression in activated alveolar macrophages: Decreased NF-kappaB activation and IkappaB kinase activity. J. Immunol. (Baltim. Md. 1950) 2001, 167, 2275–2281. [Google Scholar] [CrossRef] [Green Version]
- Klamt, F.; Shacter, E. Taurine chloramine, an oxidant derived from neutrophils, induces apoptosis in human B lymphoma cells through mitochondrial damage. J. Biol. Chem. 2005, 280, 21346–21352. [Google Scholar] [CrossRef] [Green Version]
- Kim, B.S.; Cho, I.S.; Park, S.; Schuller-Levis, G.; Levis, W.; Park, E. Taurine chloramine inhibits NO and TNF-α production in zymosan plus interferon-γ activated RAW 264.7 cells. J. Drugs Dermatol. 2011, 10, 659. [Google Scholar]
- Kim, B.S.; Spinner, D.S.; Kascsak, R.J.; Park, S.Y.; Cho, I.S.; Schuller-Levis, G.; Park, E. Inflammatory mediators are inhibited by a taurine metabolite in CpG oligodeoxynucleotide and IFN-r activated macrophage cell line. J. Drugs Dermatol. 2013, 12, 551–557. [Google Scholar]
- Kim, J.W.; Kim, C. Inhibition of LPS-induced NO production by taurine chloramine in macrophages is mediated though Ras-ERK-NF-κB. Biochem. Pharmacol. 2005, 70, 1352–1360. [Google Scholar] [CrossRef]
- Kanayama, A.; Inoue, J.-i.; Sugita-Konishi, Y.; Shimizu, M.; Miyamoto, Y. Oxidation of IκBα at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-κB activation. J. Biol. Chem. 2002, 277, 24049–24056. [Google Scholar] [CrossRef] [Green Version]
- Shishido, T.; Nozaki, N.; Takahashi, H.; Arimoto, T.; Niizeki, T.; Koyama, Y.; Abe, J.-i.; Takeishi, Y.; Kubota, I. Central role of endogenous Toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury. Biochem. Biophys. Res. Commun. 2006, 345, 1446–1453. [Google Scholar] [CrossRef]
- Madan, M.; Amar, S. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: Proteomic findings. PLoS ONE 2008, 3, e3204. [Google Scholar] [CrossRef] [Green Version]
- Lee, G.-L.; Chang, Y.-W.; Wu, J.-Y.; Wu, M.-L.; Wu, K.K.; Yet, S.-F.; Kuo, C.-C. TLR 2 Induces Vascular Smooth Muscle Cell Migration Through cAMP Response Element−Binding Protein−Mediated Interleukin-6 Production. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2751–2760. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.-X.; Lv, X.-X.; Wang, J.-P.; Yan, H.-M.; Wang, Z.-Y.; Liu, H.-Z.; Fu, X.-M.; Hu, Z.-W. Blocking TLR2 activity diminishes and stabilizes advanced atherosclerotic lesions in apolipoprotein E-deficient mice. Acta Pharmacol. Sin. 2013, 34, 1025–1035. [Google Scholar] [CrossRef] [PubMed]
- Qu, D.; Wang, L.; Huo, M.; Song, W.; Lau, C.-W.; Xu, J.; Xu, A.; Yao, X.; Chiu, J.-J.; Tian, X.Y. Focal TLR4 activation mediates disturbed flow-induced endothelial inflammation. Cardiovasc. Res. 2020, 116, 226–236. [Google Scholar] [CrossRef]
- Stoll, L.L.; Denning, G.M.; Weintraub, N.L. Endotoxin, TLR4 signaling and vascular inflammation: Potential therapeutic targets in cardiovascular disease. Curr. Pharm. Des. 2006, 12, 4229–4245. [Google Scholar] [CrossRef] [PubMed]
- Michelsen, K.S.; Wong, M.H.; Shah, P.K.; Zhang, W.; Yano, J.; Doherty, T.M.; Akira, S.; Rajavashisth, T.B.; Arditi, M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA 2004, 101, 10679–10684. [Google Scholar] [CrossRef] [Green Version]
- Higashimori, M.; Tatro, J.B.; Moore, K.J.; Mendelsohn, M.E.; Galper, J.B.; Beasley, D. Role of Toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein e–deficient mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 50–57. [Google Scholar] [CrossRef] [Green Version]
- Yin, Y.; Liao, S.; Zhang, M.; Liu, Y.; Li, B.; Zhou, Y.; Chen, L.; Gao, C.; Li, J.; Zhang, L. TLR4-mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression. Cell Death Dis. 2014, 5, e1574. [Google Scholar] [CrossRef] [Green Version]
- Chávez-Sánchez, L.; Garza-Reyes, M.G.; Espinosa-Luna, J.E.; Chávez-Rueda, K.; Legorreta-Haquet, M.V.; Blanco-Favela, F. The role of TLR2, TLR4 and CD36 in macrophage activation and foam cell formation in response to oxLDL in humans. Hum. Immunol. 2014, 75, 322–329. [Google Scholar] [CrossRef]
- Dange, R.B.; Agarwal, D.; Masson, G.S.; Vila, J.; Wilson, B.; Nair, A.; Francis, J. Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc. Res. 2014, 103, 17–27. [Google Scholar] [CrossRef]
- Wijnand, K.; Cheng, C.; Pasterkamp, G.; Duckers, H.J. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010, 209, 314–320. [Google Scholar]
- Yang, J.; Chen, L.; Yang, J.; Ding, J.; Rong, H.; Dong, W.; Li, X. High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K/Akt pathway activation. Mol. Biol. Rep. 2012, 39, 3361–3367. [Google Scholar] [CrossRef]
- Ma, C.; Ouyang, Q.; Huang, Z.; Chen, X.; Lin, Y.; Hu, W.; Lin, L. Toll-like receptor 9 inactivation alleviated atherosclerotic progression and inhibited macrophage polarized to M1 phenotype in ApoE−/− mice. Dis. Markers 2015. [Google Scholar] [CrossRef] [PubMed]
- Krogmann, A.O.; Lüsebrink, E.; Steinmetz, M.; Asdonk, T.; Lahrmann, C.; Lütjohann, D.; Nickenig, G.; Zimmer, S. Proinflammatory stimulation of toll-like receptor 9 with high dose CpG ODN 1826 impairs endothelial regeneration and promotes atherosclerosis in mice. PLoS ONE 2016, 11, e0146326. [Google Scholar] [CrossRef]
- Beyranvand, M.R.; Kadkhodai Khalafi, M.; Roshan, V.D.; Choobineh, S.; Parsa, S.A.; Piranfar, M.A. Effect of taurine supplementation on exercise capacity of patients with heart failure. J. Cardiol. 2011, 57, 333–337. [Google Scholar] [CrossRef] [Green Version]
- Van Craenenbroeck, E.M.; Beckers, P.J.; Possemiers, N.M.; Wuyts, K.; Frederix, G.; Hoymans, V.Y.; Wuyts, F.; Paelinck, B.P.; Vrints, C.J.; Conraads, V.M. Exercise acutely reverses dysfunction of circulating angiogenic cells in chronic heart failure. Eur. Heart J. 2010, 31, 1924–1934. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahmadian, M.; Roshan, V.D.; Aslani, E.; Stannard, S.R. Taurine supplementation has anti-atherogenic and anti-inflammatory effects before and after incremental exercise in heart failure. Ther. Adv. Cardiovasc. Dis. 2017, 11, 185–194. [Google Scholar] [CrossRef]
- Jeejeebhoy, F.; Keith, M.; Freeman, M.; Barr, A.; McCall, M.; Kurian, R.; Mazer, D.; Errett, L. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am. Heart J. 2002, 143, 1092–1100. [Google Scholar] [CrossRef]
- Azuma, J.; Sawamura, A.; Awata, N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn. Circ. J. 1992, 56, 95–99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schaffer, S.W.; Shimada-Takaura, K.; Jong, C.J.; Ito, T.; Takahashi, K. Impaired energy metabolism of the taurine-deficient heart. Amino Acids 2016, 48, 549–558. [Google Scholar] [CrossRef]
- Wang, J.; Qi, C.; Liu, L.; Zhao, L.; Cui, W.; Tian, Y.; Liu, B.; Li, J. Taurine Protects Primary Neonatal Cardiomyocytes Against Apoptosis Induced by Hydrogen Peroxide. Int. Heart J. 2018, 59, 190–196. [Google Scholar] [CrossRef] [Green Version]
- Sun, Q.; Wang, B.; Li, Y.; Sun, F.; Li, P.; Xia, W.; Zhou, X.; Li, Q.; Wang, X.; Chen, J.; et al. Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension: Randomized, Double-Blind, Placebo-Controlled Study. Hypertension 2016, 67, 541–549. [Google Scholar] [CrossRef] [Green Version]
- Militante, J.D.; Lombardini, J.B. Treatment of hypertension with oral taurine: Experimental and clinical studies. Amino Acids 2002, 23, 381–393. [Google Scholar] [CrossRef] [PubMed]
- Van Hove, J.L.K.; Freehauf, C.L.; Ficicioglu, C.; Pena, L.D.M.; Moreau, K.L.; Henthorn, T.K.; Christians, U.; Jiang, H.; Cowan, T.M.; Young, S.P.; et al. Biomarkers of oxidative stress, inflammation, and vascular dysfunction in inherited cystathionine β-synthase deficient homocystinuria and the impact of taurine treatment in a phase 1/2 human clinical trial. J. Inherit. Metab. Dis. 2019, 42, 424–437. [Google Scholar] [CrossRef]
- Moloney, M.A.; Casey, R.G.; O’Donnell, D.H.; Fitzgerald, P.; Thompson, C.; Bouchier-Hayes, D.J. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diabetes Vasc. Dis. Res. 2010, 7, 300–310. [Google Scholar] [CrossRef]
- Franconi, F.; Bennardini, F.; Mattana, A.; Miceli, M.; Ciuti, M.; Mian, M.; Gironi, A.; Anichini, R.; Seghieri, G. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: Effects of taurine supplementation. Am. J. Clin. Nutr. 1995, 61, 1115–1119. [Google Scholar] [CrossRef] [Green Version]
- Sak, D.; Erdenen, F.; Müderrisoglu, C.; Altunoglu, E.; Sozer, V.; Gungel, H.; Guler, P.A.; Sak, T.; Uzun, H. The Relationship between Plasma Taurine Levels and Diabetic Complications in Patients with Type 2 Diabetes Mellitus. Biomolecules 2019, 9, 96. [Google Scholar] [CrossRef] [Green Version]
- Maleki, V.; Alizadeh, M.; Esmaeili, F.; Mahdavi, R. The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Amino Acids 2020, 52, 905–914. [Google Scholar] [CrossRef] [PubMed]
- Shari, F.H.; Dawood, H.; Hassan, J.K.; ALJazeari, Q.A.; Najm, M.A.; Salahuddin, A.; Al-Salman, H. To study the effect of taurine on the effects of vital bones and regulate the level of glucose in type II diabetes. Int. J. Res. Pharm. Sci. 2019, 10, 2545–2551. [Google Scholar] [CrossRef]
- Maleki, V.; Mahdavi, R.; Hajizadeh-Sharafabad, F.; Alizadeh, M. The effects of taurine supplementation on oxidative stress indices and inflammation biomarkers in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetol. Metab. Syndr. 2020, 12, 9. [Google Scholar] [CrossRef]
- Esmaeili, F.; Maleki, V.; Kheirouri, S.; Alizadeh, M. The effects of taurine supplementation on metabolic profiles, pentosidine, soluble receptor of advanced glycation end products and methylglyoxal in patients with type 2 diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Can. J. Diabetes 2020. [Google Scholar] [CrossRef]
Ref. | Subject | Dose/Time | Outcome |
---|---|---|---|
[205,207] | Heart Failure | 1500 mg/day, 2 weeks | Improved exercise capacity, reduced TC/HDL-c, and reduced hsCRP |
[208] | Chronic Heart Failure | 3000 mg/day, 30–45 days | Decreased left ventricular end-diastolic volume with left ventricular dysfunction before revascularization |
[209] | Chronic Heart Failure | 3000 mg/day, 6 weeks | Improvement in systolic left ventricular function |
[19] | Cardiomyopathy | 100 mg/day, 24 months | Restored taurine concentration and corrected left ventricular dysfunction |
[212] | Stage 1 hypertension | 1600 mg/day, 12 weeks | Improved vasodilation and reduced blood pressure |
[213] | Hypertension | 6000 mg/day, 7 days | Reduced blood pressure |
[214] | VascularDysfunction induced by CBS deficiency | 5000 mg/day, 6 days | Improved vasodilation |
[215] | Type-2 diabetes with vascular dysfunction | 1500 mg/day, 2 weeks | Reversed vascular dysfunction |
[216] | Type-2 diabetes | 1500 mg/day, 90 days | Decreased platelet aggregation |
[218] | Type-2 diabetes | 3000 mg/day, 8 weeks | Decreased FBS, triglycerides, and LDL-c |
[220] | Type-2 diabetes | 3000 mg/day, 8 weeks | Increased SOD and decreased hsCRP, TNF-α, and IL-6 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Qaradakhi, T.; Gadanec, L.K.; McSweeney, K.R.; Abraham, J.R.; Apostolopoulos, V.; Zulli, A. The Anti-Inflammatory Effect of Taurine on Cardiovascular Disease. Nutrients 2020, 12, 2847. https://doi.org/10.3390/nu12092847
Qaradakhi T, Gadanec LK, McSweeney KR, Abraham JR, Apostolopoulos V, Zulli A. The Anti-Inflammatory Effect of Taurine on Cardiovascular Disease. Nutrients. 2020; 12(9):2847. https://doi.org/10.3390/nu12092847
Chicago/Turabian StyleQaradakhi, Tawar, Laura Kate Gadanec, Kristen Renee McSweeney, Jemma Rose Abraham, Vasso Apostolopoulos, and Anthony Zulli. 2020. "The Anti-Inflammatory Effect of Taurine on Cardiovascular Disease" Nutrients 12, no. 9: 2847. https://doi.org/10.3390/nu12092847